NovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of “Hold” from Analysts

Shares of NovoCure Limited (NASDAQ:NVCR) have been given a consensus rating of “Hold” by the seven brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $26.6429.

NVCR has been the subject of several research reports. HC Wainwright increased their target price on NovoCure from $39.00 to $47.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings reissued a “sell (e+)” rating on shares of NovoCure in a report on Thursday, January 22nd. Wedbush reiterated a “neutral” rating and set a $18.00 price target on shares of NovoCure in a report on Thursday, January 15th. Evercore set a $20.00 price objective on NovoCure in a report on Monday, January 5th. Finally, JPMorgan Chase & Co. cut their target price on NovoCure from $25.00 to $23.00 and set a “neutral” rating on the stock in a report on Monday, October 27th.

NovoCure Stock Performance

Shares of NovoCure stock opened at $10.99 on Monday. The company’s 50 day moving average price is $12.88 and its two-hundred day moving average price is $12.61. The firm has a market capitalization of $1.23 billion, a P/E ratio of -6.83 and a beta of 0.73. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.55 and a quick ratio of 1.50. NovoCure has a fifty-two week low of $9.82 and a fifty-two week high of $22.95.

Key Headlines Impacting NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: FDA approval expands commercial opportunity — The U.S. FDA cleared Optune Pax for locally advanced pancreatic cancer, giving NovoCure a new approved indication that could materially broaden TTFields usage beyond brain tumors and boost future revenue. Novocure wins FDA nod for Optune Pax as pancreatic cancer treatment
• Positive Sentiment: Big near-term market reaction — Multiple outlets report the stock surged sharply (20–30%+) on the approval, reflecting strong investor enthusiasm for the new indication. That buying lifted visibility and trading volume. NovoCure (NVCR) Is Up 23.6% After Landmark FDA Nod For Optune Pax In Pancreatic Cancer
• Positive Sentiment: Longer-term expansion case highlighted by analysts — Commentary and analysis point to a meaningful addressable‑market expansion if adoption and reimbursement follow, supporting a larger revenue runway over several years. NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity Approaching
• Neutral Sentiment: Valuation and modeling questions remain — Coverage is focusing on how to value the new indication, timing of uptake, and assumptions for pricing/reimbursement; investors are debating how much of the approval is already priced into the rally. Assessing NovoCure (NVCR) Valuation After FDA Approval Of Optune Pax For Pancreatic Cancer
• Neutral Sentiment: Broader market context influencing moves — Nasdaq/futures action and overall tape volatility have accentuated the stock’s intraday swings as macro flows and sector momentum interact with company‑specific news. Stock Market Today: Dow Jones, S&P 500 Futures Gain After Strong Job Report—Micron, Novocure, Fastly In Focus
• Negative Sentiment: Profit‑taking and short‑term pullback — After the initial surge, some investors took profits and the stock pulled back; with elevated short‑term volatility, downside risk remains if adoption/reimbursement timelines disappoint or if broader selling resumes. What’s Happening With NovoCure Stock?

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Empowered Funds LLC bought a new position in NovoCure during the fourth quarter worth $33,000. SJS Investment Consulting Inc. bought a new stake in NovoCure during the third quarter valued at $41,000. Kestra Advisory Services LLC acquired a new stake in NovoCure during the 4th quarter worth about $49,000. Larson Financial Group LLC raised its position in shares of NovoCure by 662.1% in the 3rd quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock worth $53,000 after acquiring an additional 3,562 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of NovoCure by 17.1% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,307 shares of the medical equipment provider’s stock worth $77,000 after acquiring an additional 629 shares in the last quarter. Institutional investors and hedge funds own 84.61% of the company’s stock.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.